Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design

Sharon D. Yeatts, Joseph P. Broderick, Anjan Chatterjee, Edward C. Jauch, Steven R. Levine, Jose G Romano, Jeffrey L. Saver, Achala Vagal, Barbara Purdon, Jenny Devenport, Pooja Khatri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rationale: Over half of acute ischemic stroke patients have a low National Institutes of Health Stroke Scale of 0–5 and up to two-thirds may not appear clearly disabled at presentation. The efficacy of intravenous alteplase for the latter group is not known. Aim: Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) was designed to evaluate the safety and efficacy of intravenous alteplase for the treatment of acute ischemic stroke with National Institutes of Health Stroke Scale 0–5 and without clearly disabling deficits. Sample size estimates: A maximum of 948 subjects were required to test the superiority hypothesis with 80% power, according to a one-sided 0.025 level of significance. Methods and design: PRISMS was a multicenter, randomized, double-blind, placebo-controlled phase 3b clinical trial. Patients were randomized to the active arm (intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo) or the control arm (intravenous alteplase placebo plus active oral aspirin dose of 325 mg). Study outcome: The primary efficacy endpoint was favorable functional outcome, defined as a modified Rankin Scale score 0 or 1 assessed at 90-day postrandomization.

Original languageEnglish (US)
JournalInternational Journal of Stroke
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

National Institutes of Health (U.S.)
Tissue Plasminogen Activator
Stroke
Placebos
Aspirin
Therapeutics
Sample Size
Outcome Assessment (Health Care)
Clinical Trials
Safety

Keywords

  • Acute stroke therapy
  • alteplase
  • intervention
  • ischemic stroke
  • methodology
  • protocols

ASJC Scopus subject areas

  • Neurology

Cite this

Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS) : Rationale and design. / Yeatts, Sharon D.; Broderick, Joseph P.; Chatterjee, Anjan; Jauch, Edward C.; Levine, Steven R.; Romano, Jose G; Saver, Jeffrey L.; Vagal, Achala; Purdon, Barbara; Devenport, Jenny; Khatri, Pooja.

In: International Journal of Stroke, 01.01.2018.

Research output: Contribution to journalArticle

Yeatts, Sharon D. ; Broderick, Joseph P. ; Chatterjee, Anjan ; Jauch, Edward C. ; Levine, Steven R. ; Romano, Jose G ; Saver, Jeffrey L. ; Vagal, Achala ; Purdon, Barbara ; Devenport, Jenny ; Khatri, Pooja. / Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS) : Rationale and design. In: International Journal of Stroke. 2018.
@article{8265be4670264cfeae72f64a0ec1586a,
title = "Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design",
abstract = "Rationale: Over half of acute ischemic stroke patients have a low National Institutes of Health Stroke Scale of 0–5 and up to two-thirds may not appear clearly disabled at presentation. The efficacy of intravenous alteplase for the latter group is not known. Aim: Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) was designed to evaluate the safety and efficacy of intravenous alteplase for the treatment of acute ischemic stroke with National Institutes of Health Stroke Scale 0–5 and without clearly disabling deficits. Sample size estimates: A maximum of 948 subjects were required to test the superiority hypothesis with 80{\%} power, according to a one-sided 0.025 level of significance. Methods and design: PRISMS was a multicenter, randomized, double-blind, placebo-controlled phase 3b clinical trial. Patients were randomized to the active arm (intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo) or the control arm (intravenous alteplase placebo plus active oral aspirin dose of 325 mg). Study outcome: The primary efficacy endpoint was favorable functional outcome, defined as a modified Rankin Scale score 0 or 1 assessed at 90-day postrandomization.",
keywords = "Acute stroke therapy, alteplase, intervention, ischemic stroke, methodology, protocols",
author = "Yeatts, {Sharon D.} and Broderick, {Joseph P.} and Anjan Chatterjee and Jauch, {Edward C.} and Levine, {Steven R.} and Romano, {Jose G} and Saver, {Jeffrey L.} and Achala Vagal and Barbara Purdon and Jenny Devenport and Pooja Khatri",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1747493018765269",
language = "English (US)",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS)

T2 - Rationale and design

AU - Yeatts, Sharon D.

AU - Broderick, Joseph P.

AU - Chatterjee, Anjan

AU - Jauch, Edward C.

AU - Levine, Steven R.

AU - Romano, Jose G

AU - Saver, Jeffrey L.

AU - Vagal, Achala

AU - Purdon, Barbara

AU - Devenport, Jenny

AU - Khatri, Pooja

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Rationale: Over half of acute ischemic stroke patients have a low National Institutes of Health Stroke Scale of 0–5 and up to two-thirds may not appear clearly disabled at presentation. The efficacy of intravenous alteplase for the latter group is not known. Aim: Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) was designed to evaluate the safety and efficacy of intravenous alteplase for the treatment of acute ischemic stroke with National Institutes of Health Stroke Scale 0–5 and without clearly disabling deficits. Sample size estimates: A maximum of 948 subjects were required to test the superiority hypothesis with 80% power, according to a one-sided 0.025 level of significance. Methods and design: PRISMS was a multicenter, randomized, double-blind, placebo-controlled phase 3b clinical trial. Patients were randomized to the active arm (intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo) or the control arm (intravenous alteplase placebo plus active oral aspirin dose of 325 mg). Study outcome: The primary efficacy endpoint was favorable functional outcome, defined as a modified Rankin Scale score 0 or 1 assessed at 90-day postrandomization.

AB - Rationale: Over half of acute ischemic stroke patients have a low National Institutes of Health Stroke Scale of 0–5 and up to two-thirds may not appear clearly disabled at presentation. The efficacy of intravenous alteplase for the latter group is not known. Aim: Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) was designed to evaluate the safety and efficacy of intravenous alteplase for the treatment of acute ischemic stroke with National Institutes of Health Stroke Scale 0–5 and without clearly disabling deficits. Sample size estimates: A maximum of 948 subjects were required to test the superiority hypothesis with 80% power, according to a one-sided 0.025 level of significance. Methods and design: PRISMS was a multicenter, randomized, double-blind, placebo-controlled phase 3b clinical trial. Patients were randomized to the active arm (intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo) or the control arm (intravenous alteplase placebo plus active oral aspirin dose of 325 mg). Study outcome: The primary efficacy endpoint was favorable functional outcome, defined as a modified Rankin Scale score 0 or 1 assessed at 90-day postrandomization.

KW - Acute stroke therapy

KW - alteplase

KW - intervention

KW - ischemic stroke

KW - methodology

KW - protocols

UR - http://www.scopus.com/inward/record.url?scp=85044575959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044575959&partnerID=8YFLogxK

U2 - 10.1177/1747493018765269

DO - 10.1177/1747493018765269

M3 - Article

C2 - 29570044

AN - SCOPUS:85044575959

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

ER -